Thrv-1268
Heart Failure
Thryv Therapeutics, Inc.Phase 1Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 81/ 100
Competitive context
26 Active assets in the Heart Failure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Empagliflozin Jacob Moller | Phase 4 | BB |
Finerenone Hospital de Messejana Dr. Carlos Alberto Studart Gomes | Phase 4 | BB |
Semaglutide University Medical Centre Ljubljana | Phase 2/3 | BB |
CARVEDILOL Abramson Cancer Center at Penn Medicine | Phase 3 | BB |
Rivaroxaban Janssen Research & Development, LLC | Phase 3 | B |
View all 40 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →